Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015391 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TRIM24TRIM33L3MBTL1ESR1 | |
| SCHEMBL6757690 | 0.91 | CRBN (0.36) | ALDH1A1TRIM24TRIM33L3MBTL1ESR1 | |
| SCHEMBL6757693 | 0.91 | CRBN (0.36) | ALDH1A1TRIM24TRIM33L3MBTL1ESR1 | |
| SCHEMBL11866693 | 0.85 | CRBN (0.36) | CRBN | |
| SCHEMBL1903325 | 0.84 | CRBN (0.33) | ALDH1A1TRIM24TRIM33CRBN | |
| SCHEMBL2982384 | 0.81 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1ESR1ESR2ACHE | |
| SCHEMBL2988042 | 0.81 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1ESR1ESR2ACHE | |
| SCHEMBL17223833 | 0.77 | — | — | |
| SCHEMBL3646429 | 0.75 | MEN1 (0.48) | ALDH1A1TRIM24TRIM33 | |
| SCHEMBL731994 | 0.75 | MAPT (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114698371-B | Adhesive for skin adhesion, cured product, and adhesive tape for skin adhesion | 东洋油墨SC控股株式会社 | 2023-08-15 | — | — | CN | disclosed |
| CN-115745765-A | Preparation method of p-bromoalkylcyclohexanone compounds | 浙大宁波理工学院 | 2023-03-07 | — | — | CN | disclosed |
| US-20220257774-A1 | AROMATIC AMINE AR AHD BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | HINOVA PHARMACEUTICALS INC. (CN) | 2022-08-18 | — | — | US | disclosed |
| CN-114698371-A | Adhesive for skin adhesion, cured product, and adhesive tape for skin adhesion | 东洋油墨SC控股株式会社 | 2022-07-01 | — | — | CN | disclosed |
| EP-3971176-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | Hinova Pharmaceuticals Inc. (CN) | 2022-03-23 | — | — | EP | disclosed |
| US-20210393674-A1 | OZONOLYSIS FOR ACTIVATION OF COMPOUNDS AND DEGRADATION OF OZONE | AIR CROSS, INC | 2021-12-23 | — | — | US | disclosed |
| CN-113710378-A | Solution of hydroxyl-containing terminal urethane prepolymer and method for producing same, adhesive, and adhesive sheet and method for producing same | 东洋油墨SC控股株式会社 | 2021-11-26 | — | — | CN | disclosed |
| CN-109306257-B | Urethane adhesive, adhesive sheet, and display | 东洋油墨SC控股株式会社 | 2021-06-15 | — | — | CN | disclosed |
| CN-108348894-A | Ozonolysis for compound activation and ozonolysis | 空气交叉股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3349893-A1 | OZONOLYSIS FOR ACTIVATION OF COMPOUNDS AND DEGRADATION OF OZONE | Air Cross Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-6716865-B1 | SUBSTITUTED AT THE 2 POSITION; A SULFAMATE BOUND VIA OXYGEN TO THE PHENYL PART OF THE RING STRUCTURE; SULFAMOYLATION; STEROID SULFATASE INHIBITOR, ACNE | NOVARTIS AG (CH) | 2004-04-06 | — | — | US | disclosed |
| US-3954716-A | HIGH MOLECULAR WEIGHT | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | ALDH1A1 1614/4885TRIM24 1898/4885TRIM33 2359/4885 |
| US-20220257774-A1 | AROMATIC AMINE AR AHD BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | AR, BRD4, BRDT | ALDH1A1 1464/4885TRIM24 209/4885TRIM33 983/4885 |
| US-20210393674-A1 | OZONOLYSIS FOR ACTIVATION OF COMPOUNDS AND DEGRADATION OF OZONE | DUOX1, DUOX2, AOX1 | ALDH1A1 1635/4885TRIM24 3549/4885TRIM33 3984/4885 |
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | ALDH1A1 2406/4885TRIM24 2714/4885TRIM33 1649/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | ALDH1A1 1614/4885TRIM24 1898/4885TRIM33 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.